Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Lessons learnt after the introduction of the seven valent-pneumococcal conjugate vaccine toward broader spectrum conjugate vaccines.

Falup-Pecurariu O.

Biomed J. 2012 Nov-Dec;35(6):450-6. doi: 10.4103/2319-4170.104409. Review.

2.

Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.

Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R.

Pediatr Infect Dis J. 2009 Apr;28(4):277-82. doi: 10.1097/INF.0b013e31818e0e2e.

PMID:
19258924
3.

Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L.

BMC Infect Dis. 2012 Sep 7;12:207. doi: 10.1186/1471-2334-12-207. Review.

4.

Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.

Link-Gelles R, Taylor T, Moore MR; Active Bacterial Core Surveillance Team.

Vaccine. 2013 May 24;31(22):2572-7. doi: 10.1016/j.vaccine.2013.03.049. Epub 2013 Apr 11.

PMID:
23583813
5.

Pneumococcal serotype evolution in Western Europe.

Tin Tin Htar M, Christopoulou D, Schmitt HJ.

BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x. Review.

6.
8.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.

PMID:
23312274
9.

Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012.

Aguiar SI, Brito MJ, Horacio AN, Lopes JP, Ramirez M, Melo-Cristino J; Portuguese Group for the Study of Streptococcal Infections; Portuguese Study Group of Invasive Pneumococcal Disease of the Paediatric Infectious Disease Society.

Euro Surveill. 2014 Mar 27;19(12):20750.

10.

Dynamics of Streptococcus pneumoniae serotypes causing acute otitis media isolated from children with spontaneous middle-ear drainage over a 12-year period (1999-2010) in a region of northern Spain.

Alonso M, Marimon JM, Ercibengoa M, Pérez-Yarza EG, Pérez-Trallero E.

PLoS One. 2013;8(1):e54333. doi: 10.1371/journal.pone.0054333. Epub 2013 Jan 22.

11.

Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.

Harboe ZB, Valentiner-Branth P, Ingels H, Rasmussen JN, Andersen PH, Bjerre CC, Goldblatt D, Ashton L, Haston M, Konradsen HB, Lambertsen L; Danish Pneumococcal Surveillance Collaborating Group.

PLoS One. 2013;8(1):e51460. doi: 10.1371/journal.pone.0051460. Epub 2013 Jan 24.

12.
13.

Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.

Sherwin RL, Gray S, Alexander R, McGovern PC, Graepel J, Pride MW, Purdy J, Paradiso P, File TM Jr.

J Infect Dis. 2013 Dec 1;208(11):1813-20. doi: 10.1093/infdis/jit506. Epub 2013 Oct 2.

PMID:
24092845
14.

Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):253-7.

15.

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands.

Knol MJ, Wagenvoort GH, Sanders EA, Elberse K, Vlaminckx BJ, de Melker HE, van der Ende A.

Emerg Infect Dis. 2015 Nov;21(11):2040-4. doi: 10.3201/eid2111.140780. Erratum in: Emerg Infect Dis. 2016 Jan;22(1):161.

16.

The future of pneumococcal disease prevention.

Rodgers GL, Klugman KP.

Vaccine. 2011 Sep 14;29 Suppl 3:C43-8. doi: 10.1016/j.vaccine.2011.07.047.

PMID:
21896352
17.

Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine.

McEllistrem MC, Adams JM, Patel K, Mendelsohn AB, Kaplan SL, Bradley JS, Schutze GE, Kim KS, Mason EO, Wald ER.

Clin Infect Dis. 2005 Jun 15;40(12):1738-44. Epub 2005 May 11.

PMID:
15909260
18.

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.

Miller E, Andrews NJ, Waight PA, Slack MP, George RC.

Vaccine. 2011 Nov 15;29(49):9127-31. doi: 10.1016/j.vaccine.2011.09.112. Epub 2011 Oct 5.

PMID:
21983361
19.

Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule.

Wiertsema SP, Kirkham LA, Corscadden KJ, Mowe EN, Bowman JM, Jacoby P, Francis R, Vijayasekaran S, Coates HL, Riley TV, Richmond P.

Vaccine. 2011 Jul 18;29(32):5163-70. doi: 10.1016/j.vaccine.2011.05.035. Epub 2011 May 27.

PMID:
21621576
20.

Improving the protection against Streptococcus pneumoniae with the new generation 13-valent pneumococcal conjugate vaccine.

Durando P, Alicino C, De Florentiis D, Martini M, Icardi G.

J Prev Med Hyg. 2012 Jun;53(2):68-77. Review.

PMID:
23240163

Supplemental Content

Support Center